Key facts
- This page summarizes Joseph Cappello's Form 4 filing for GENELUX Corp (GNLX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 08 Jul 2024, 16:30.
Joseph Cappello - 19 Feb 2024 Form 4 Insider Report for GENELUX Corp (GNLX)
- Reporting relationship
- VP, Pharmaceutical Development
- Issuer ticker
- GNLX
- Reported as of
- 19 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Jul 2024, 16:30:14 UTC
- Prior SEC filing
- 12 Sep 2023
- Next SEC filing
- 18 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sean Ryder, Esq., Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Joseph Cappello filed Form 4 for GENELUX Corp (GNLX) on 08 Jul 2024.
Change
- Previous filing in this sequence was filed on 12 Sep 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GNLX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +3,661
- Change %
- +64%
- Price
- $0.000000
- Shares after
- 9,396
- Date
- 19 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
GNLX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +11,557
- Change %
- +123%
- Price
- $0.000000
- Shares after
- 20,953
- Date
- 14 Mar 2024
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs are fully vested as of February 17, 2024.
Footnote F2
Represents RSUs that are fully vested as of March 14, 2024.